JOP20190002A1 - أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم - Google Patents
أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهمInfo
- Publication number
- JOP20190002A1 JOP20190002A1 JOP/2019/0002A JOP20190002A JOP20190002A1 JO P20190002 A1 JOP20190002 A1 JO P20190002A1 JO P20190002 A JOP20190002 A JO P20190002A JO P20190002 A1 JOP20190002 A1 JO P20190002A1
- Authority
- JO
- Jordan
- Prior art keywords
- antibodies
- same
- oncology
- producing
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2016128487A RU2656181C1 (ru) | 2016-07-13 | 2016-07-13 | Анти-pd-1-антитела, способ их получения и способ применения |
| PCT/RU2017/050056 WO2018013017A1 (ru) | 2016-07-13 | 2017-07-04 | Анти-pd-1-антитела, способ их получения и способ применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190002A1 true JOP20190002A1 (ar) | 2019-01-10 |
Family
ID=60953256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0002A JOP20190002A1 (ar) | 2016-07-13 | 2017-06-16 | أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11136408B2 (enExample) |
| EP (1) | EP3486257A4 (enExample) |
| JP (1) | JP6993992B2 (enExample) |
| KR (1) | KR102482710B1 (enExample) |
| CN (1) | CN110023335B (enExample) |
| BR (1) | BR112019000436A2 (enExample) |
| CA (1) | CA3021372A1 (enExample) |
| CL (1) | CL2018003407A1 (enExample) |
| CO (1) | CO2019001246A2 (enExample) |
| CR (1) | CR20190009A (enExample) |
| EC (1) | ECSP19010852A (enExample) |
| JO (1) | JOP20190002A1 (enExample) |
| MA (1) | MA44547B1 (enExample) |
| MX (1) | MX2018014937A (enExample) |
| NI (1) | NI201900002A (enExample) |
| NZ (1) | NZ750221A (enExample) |
| PE (1) | PE20190450A1 (enExample) |
| PH (1) | PH12018550179A1 (enExample) |
| RU (1) | RU2656181C1 (enExample) |
| WO (1) | WO2018013017A1 (enExample) |
| ZA (1) | ZA201900792B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102220275B1 (ko) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
| CN117586401A (zh) | 2017-01-20 | 2024-02-23 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其用途 |
| IL269970B (en) | 2017-04-14 | 2022-09-01 | Tallac Therapeutics Inc | Polynucleotides that modulate the immune system, their antibody binding, and methods of using them |
| KR102692379B1 (ko) | 2017-06-05 | 2024-08-05 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 사용 방법 |
| TN2020000015A1 (en) | 2017-08-03 | 2021-10-04 | Amgen Inc | Interleukin-21 muteins and methods of treatment |
| SG11202005605SA (en) | 2018-01-12 | 2020-07-29 | Amgen Inc | Anti-pd-1 antibodies and methods of treatment |
| WO2019148410A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| CN112424231B (zh) * | 2018-07-19 | 2022-09-13 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其剂量和用途 |
| CN109652453B (zh) * | 2018-12-29 | 2021-04-06 | 杭州科兴生物科技有限公司 | 一种基于pd-1/pdl-1阻断功能及生物效应的抗癌药物快速筛选方法 |
| WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| AU2020290971A1 (en) * | 2019-06-14 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| TWI844666B (zh) * | 2019-08-22 | 2024-06-11 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途 |
| RU2753282C2 (ru) | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| US11920136B2 (en) | 2020-02-28 | 2024-03-05 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| US20250270320A1 (en) * | 2020-12-10 | 2025-08-28 | Eutilex Co., Ltd. | Anti-pd-1 antibody and uses thereof |
| KR20230163503A (ko) * | 2021-03-31 | 2023-11-30 | 메뤼스 엔.페. | 신규한 pd-1 결합 도메인 |
| BR112023020856A2 (pt) | 2021-04-08 | 2024-02-06 | Biocad Joint Stock Co | Uso de anticorpo para pd-1 e método de tratamento para uma neoplasia maligna |
| WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| EP4598960A1 (en) * | 2022-10-05 | 2025-08-13 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2418278A3 (en) * | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP2535354B1 (en) * | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8062852B2 (en) * | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| CN104961829B (zh) * | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| HUE041335T2 (hu) * | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| PT2992017T (pt) * | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| RS63571B9 (sr) * | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva |
| ES2819451T3 (es) * | 2014-08-08 | 2021-04-16 | Univ Leland Stanford Junior | Agentes PD-1 de alta afinidad y procedimientos de uso |
| GB201419084D0 (en) * | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
-
2016
- 2016-07-13 RU RU2016128487A patent/RU2656181C1/ru active
-
2017
- 2017-06-16 JO JOP/2019/0002A patent/JOP20190002A1/ar unknown
- 2017-07-04 WO PCT/RU2017/050056 patent/WO2018013017A1/ru not_active Ceased
- 2017-07-04 MA MA44547A patent/MA44547B1/fr unknown
- 2017-07-04 JP JP2018567611A patent/JP6993992B2/ja active Active
- 2017-07-04 KR KR1020197003862A patent/KR102482710B1/ko active Active
- 2017-07-04 BR BR112019000436A patent/BR112019000436A2/pt unknown
- 2017-07-04 EP EP17828049.1A patent/EP3486257A4/en active Pending
- 2017-07-04 PE PE2019000027A patent/PE20190450A1/es unknown
- 2017-07-04 CN CN201780055794.3A patent/CN110023335B/zh active Active
- 2017-07-04 US US16/095,800 patent/US11136408B2/en active Active
- 2017-07-04 MX MX2018014937A patent/MX2018014937A/es unknown
- 2017-07-04 NZ NZ750221A patent/NZ750221A/en unknown
- 2017-07-04 CA CA3021372A patent/CA3021372A1/en active Pending
- 2017-07-04 CR CR20190009A patent/CR20190009A/es unknown
-
2018
- 2018-10-26 PH PH12018550179A patent/PH12018550179A1/en unknown
- 2018-11-29 CL CL2018003407A patent/CL2018003407A1/es unknown
-
2019
- 2019-01-08 NI NI201900002A patent/NI201900002A/es unknown
- 2019-02-07 ZA ZA2019/00792A patent/ZA201900792B/en unknown
- 2019-02-12 CO CONC2019/0001246A patent/CO2019001246A2/es unknown
- 2019-02-13 EC ECSENADI201910852A patent/ECSP19010852A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20190450A1 (es) | 2019-03-29 |
| JP2019527543A (ja) | 2019-10-03 |
| CL2018003407A1 (es) | 2019-03-29 |
| PH12018550179A1 (en) | 2019-03-11 |
| KR102482710B1 (ko) | 2023-01-02 |
| CR20190009A (es) | 2019-06-05 |
| US20190127478A1 (en) | 2019-05-02 |
| CO2019001246A2 (es) | 2019-02-19 |
| MA44547A1 (fr) | 2020-01-31 |
| EP3486257A1 (en) | 2019-05-22 |
| MX2018014937A (es) | 2019-05-16 |
| CN110023335B (zh) | 2024-05-17 |
| EP3486257A4 (en) | 2020-03-04 |
| NZ750221A (en) | 2022-09-30 |
| ECSP19010852A (es) | 2019-06-30 |
| NI201900002A (es) | 2019-06-11 |
| CN110023335A (zh) | 2019-07-16 |
| RU2656181C1 (ru) | 2018-05-31 |
| MA44547B1 (fr) | 2021-09-30 |
| AU2017297138A2 (en) | 2019-02-21 |
| JP6993992B2 (ja) | 2022-01-14 |
| US11136408B2 (en) | 2021-10-05 |
| WO2018013017A1 (ru) | 2018-01-18 |
| ZA201900792B (en) | 2020-03-25 |
| KR20190029641A (ko) | 2019-03-20 |
| BR112019000436A2 (pt) | 2019-10-01 |
| AU2017297138A1 (en) | 2019-02-14 |
| AU2017297138A8 (en) | 2019-02-28 |
| CA3021372A1 (en) | 2018-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018550179A1 (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
| PH12020500368A1 (en) | B7-h4 antibodies and methods of use thereof | |
| ZA202311412B (en) | Anti-phf-tau antibodies and uses thereof | |
| PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| MY175878A (en) | Anti-il-17 antibodies, a method for producing and using thereof | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
| MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
| SG10201900571YA (en) | Anti-pd-1 antibodies | |
| SG10201901057UA (en) | Anti-pd-l1 antibodies | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| NZ759835A (en) | Cd38 modulating antibody | |
| EP4316596A3 (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| NZ748777A (en) | Binding molecules specific for fcγriia and uses thereof | |
| PH12019501089A1 (en) | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
| TH1901000154A (th) | แอนติบอดีต้าน pd-1, วิธีการผลิตและวิธีการใช้ของสิ่งดังกล่าว |